MVD (Mevalonate Diphosphate Decarboxylase)

The differences in serum markers seem to mirror histopathologic and molecular alterations in the MVs with potential applications into the clinic as diagnosis biomarkers. Identification of underlying molecular mechanisms of each etiology is essential to discover new specific therapeutic targets.

Our real-world study provides preliminary evidence that bevacizumab may confer differential prognostic benefits in AOC patients undergoing NAC followed by IDS, contingent upon tumor MVD quantified via CD34 immunohistochemistry, though it is important to acknowledge the lack of independent external validation for these findings. This potential biomarker-driven therapeutic heterogeneity preliminarily underscores the possibility of developing adaptive treatment algorithms that stratify patients based on angiogenic susceptibility profiles, which may lay a foundation for exploring precision administration of anti-VEGF therapy in a cost-effective paradigm.

SRF overexpression in glioblastoma is associated with increased angiogenesis and higher recurrence risk. SRF may promote tumour proliferation, differentiation, and migration, and serve as a prognostic biomarker and potential therapeutic target.

Our results highlight the similarity of biological information captured by PSMA PET and ASL perfusion imaging in GBM. The tracer uptake observed in PSMA PET can also reliably reflect the spatial heterogeneity of the microvascular distribution of GBM. These findings provide compelling support for PSMA-targeted radiotherapy as an anti-angiogenic therapeutic strategy for patients with GBM, while also advancing our understanding of the mechanisms underlying PSMA tracer uptake.

Highly significant correlation is observed among different groups of OSCC samples. CD34 shows a promising result in OSCC.

A highly significant correlation is observed among different groups of OSCC samples. CD105 is a predictive marker for neoangiogenesis in OSCC.

SRF is overexpressed in glioblastoma and closely linked to tumor angiogenesis and postoperative recurrence. High SRF expression may promote tumor progression through vascular remodeling, suggesting its potential utility as a prognostic biomarker and therapeutic target in GBM management.

We unraveled the intriguing relationship between the mevalonate pathway, CoQ10 production, and selenoprotein translation. The anti-tumor roles of 6-FMEV and atorvastatin highlight the potential of targeting the pathway as a promising therapeutic strategy for HCC.

The expression levels of VEGF and MVD are significantly increased in endometrial cancer, and both are positively correlated in endometrial cancer. MVD is related to the surgical pathological staging, lymph node metastasis, and depth of muscle wall infiltration of endometrial cancer, indicating that local neovascularization and rich blood supply play an important role in the occurrence and development of endometrial cancer. VEGF is related to the depth of muscle wall infiltration in endometrial cancer, but not to surgical pathological staging and lymph node metastasis. It is considered that other angiogenic factors besides VEGF play a role in regulating angiogenesis during surgical pathological staging and lymph node metastasis of endometrial cancer.

This study supports the potential use of CD105 expression and its quantitative indicator, the CD105 MVD score, as biomarkers for distinguishing benign thyroid nodules from malignant ones and for evaluating the prognosis of PTC.

Furthermore, there was a correlation between CIRBP mRNA expression, HIF1α mRNA expression, and MVD. Consequently, this study suggests that CIRBP may have a role in promoting angiogenesis in BC.

Decreased intratumoral CD34 positive microvessels were associated with tumor development in patients with LUAD. CD34-MVD is an independent risk factor affecting postoperative tumor recurrence in patients with LUAD and can be used as a prognostic indicator for this group of patients.